Trial
NCT03045393
Mirvetuximab Soravtansine (IMG853) in Folate Receptor Alpha-expressing TNBC
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Duke University
Collaborators
National Comprehensive Cancer Network
Condition
Breast Cancer Triple Negative
Intervention
Mirvetuximab Soravtansine (IMGN853)
Why stopped
Inadequate enrollment
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-07-05